Latest news with #regulatoryupdates
Zawya
06-08-2025
- Business
- Zawya
Deloitte Middle East introduces ME Tax Pulse as next-generation mobile app
Mubasher: Deloitte Middle East has launched ME Tax Pulse to be a next-generation mobile application designed to deliver timely, relevant, and region-specific tax insights to professionals across the region, according to a press release. The app aims to bring together real-time regulatory updates, expert commentary, and curated content across a wide spectrum of tax domains such as business tax, indirect tax, international tax, transfer pricing, M&A, and global workforce services. Tax and Legal Leader at Deloitte Middle East, Muhammad Bahemia, said: 'ME Tax Pulse puts practical, high-value content directly in the hands of professionals.' Bahemia elaborated: 'Whether it is monitoring developments, exploring technical guidance, or preparing for regulatory changes, the app supports smarter, faster access to the information professionals rely on every day.' The lead concluded: 'With ME Tax Pulse, Deloitte continues to invest in intuitive, technology-enabled tools that strengthen client connectivity and equip professionals to respond confidently to the region's evolving tax landscape.' A core feature of the app is its built-in AI Assistant, which helps users navigate Deloitte's extensive Middle East tax and legal content with greater ease and speed. It allows users to interact with Deloitte's published materials and surface the most relevant insights quickly and the assistant enhances decision support while maintaining the highest standards of professional integrity. ME Tax Pulse is tailored for professionals in the UAE, Saudi Arabia, Qatar, Kuwait, Oman, Bahrain, and Egypt, and is available free of charge on both the Apple App Store and Google Play.
Yahoo
14-07-2025
- Business
- Yahoo
Merck (NYSE:MRK) To Present Promising HIV Research Data At IAS 2025 In Kigali
Merck recently announced updates on its HIV research, which are set to be unveiled at the upcoming International AIDS Society Conference. This announcement, coupled with the company's ongoing project developments and regulatory updates, such as the FDA's acceptance of a supplemental Biologics License Application for WINREVAIR, might have bolstered investor sentiment. Over the last quarter, Merck's share price increased by 2.47%. During this period, broader market movements, including trade uncertainties affecting major indices, showed mixed directions, with the overall market staying relatively flat, suggesting Merck's performance aligned with the broader market trends. Every company has risks, and we've spotted 1 weakness for Merck you should know about. These 16 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch. The recent updates on Merck's HIV research, paired with developments related to the supplemental Biologics License Application for WINREVAIR, hold potential implications for the company's growth narrative. These advancements might positively influence Merck's revenue by bolstering its product pipeline, which is projected to introduce over 20 new growth drivers with significant commercial potential. As a result, long-term earnings forecasts could see an upward adjustment, aligning with the company's efforts to maintain leadership in key therapeutic areas. Over a five-year period, Merck's total return, encompassing both share price appreciation and dividends, was 28.14%. This is noteworthy given the 12.5% return for the US market over the past year, despite the company's underperformance relative to the broader market and industry decline. Such performance over time suggests resilience and long-term growth potential, despite facing short-term market volatility and challenges from competitors within the pharmaceuticals sector. Regarding the current share price, which sits at US$79.04, Merck's price target of US$105.02 implies a potential share price increase of 24.7%. The market's reaction to the company's recent news could be a contributing factor to bridging this gap, if the projected growth in revenue and earnings materializes effectively. Investors might consider these elements in evaluating Merck's long-term value proposition. According our valuation report, there's an indication that Merck's share price might be on the cheaper side. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NYSE:MRK. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Finextra
01-07-2025
- Business
- Finextra
AI-led RegTech startup Zango raises $4.8 million
London-based Zango AI has raised $4.8 million to overhaul financial compliance systems with AI agents. 0 The funding round was led by Nexus Venture Partners, with addittional participation from South Park Commons, Richard Davies, CEO of Allica Bank, Alan Morgan, former head of Financial Services at McKinsey (EMEA), Mark Ransford, Notion Capital, No Label Ventures and Start Ventures. Already used by Novobanco in Portugal and UK and EU neobanks, including Monzo and Juni, Zango's regulation-aware AI agents continuously track regulatory updates, identify compliance gaps in real time, and keep firms audit-ready. The firm is training Large Language Models to transform compliance into a query-based operating systemm, answering questions like: 'I want to launch a lending product in [Y] market — what do I need to do?' Ritesh Singhania, co-founder of Zango, says: "Our AI agents are paired with humans-in-the-loop to ensure 100% accuracy. Peace of mind doesn't come from a tool; it comes from a result. That's why we win against consultants — because they don't just sell software, and neither do we.' Singhania previously founded ClearGlass, a pension compliance platform, and served as head of technology at Simplitium, which was acquired by Nasdaq. Fellow co-founder Shashank Agarwal co-founded Third Watch, an AI-powered fraud detection startup which was acquired by Razorpay, and led trust and compliance engineering at PhonePe, which is gearing up for India's largest IPO. The funds raised will be used to expand teams in London & Bengaluru along with building out the other product modules for an AI-native GRC. Zango also intends to expand into other verticals of financial services as well outside of banking to insurance and asset management.
